Home
About Us
Back
About Us
Management Team
Board of Directors
Clinical Advisors
Factsheet
Pipeline
Back
Pipeline
VDA-1102 Ointment
VDA-1102 IV
VDA-1214
Therapeutic Areas
Back
Oncology
Back
Solid Tumors
Cutaneous T-Cell Lymphoma (CTCL)
Dermatology
Back
Skin Cancer
Cutaneous Squamous Cell Carcinoma (cSCC)
Actinic Keratosis
Clinical Trials
Back
VDA-1102 Ointment
Technology
Back
HK2 in Cancer
VDAC/HK2
VDAC/HK2 Modulators
News & Events
Back
Press Releases
Events
Publications
Factsheet
Contact
Back
Contact Form
Contact Details
Pipeline
Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.
read more
News
VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS
VIDAC PHARMA PHASE 2 STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION
VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2 STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS
VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT
LiteSites
|
Login
© 2016 - 2017 Vidac
To Top
